Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. [electronic resource]
Producer: 20130114Description: 844-61 p. digitalISSN:- 1941-837X
- Antipsychotic Agents -- economics
- Benzodiazepines -- economics
- Cost-Benefit Analysis
- Drug Substitution
- Female
- Health Resources -- statistics & numerical data
- Humans
- Injections -- economics
- Isoxazoles -- economics
- Male
- Markov Chains
- Models, Economic
- Olanzapine
- Paliperidone Palmitate
- Palmitates -- economics
- Quality-Adjusted Life Years
- Recurrence
- Risperidone -- economics
- Schizophrenia -- drug therapy
- Sweden -- epidemiology
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.